Advertisement
HROW vs TEVA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HROW is a StrongBuy and TEVA is a StrongBuy.
HROW's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for HROW turned positive on October 20, 2026. Looking at past instances where HROW's MACD turned positive, the stock continued to rise in 39 of 47 cases over the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where HROW's RSI Indicator exited the oversold zone, 32 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on HROW as a result. In 67 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
Following a +1.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where HROW advanced for three days, in 239 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
HROW may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HROW declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
The Aroon Indicator for HROW entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. HROW’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 87 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: HROW's P/B Ratio (73.965) is slightly higher than the industry average of (8.801). P/E Ratio (-30.293) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.270) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (4.627) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Aroon Indicator for TEVA shows an upward move is likely
TEVA's Aroon Indicator triggered a bullish signal on October 20, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 282 similar instances where the Aroon Indicator showed a similar pattern. In 217 of the 282 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 77%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 61 cases where TEVA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
Following a +2.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEVA advanced for three days, in 228 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TEVA as a result. In 57 of 78 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for TEVA turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
TEVA broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 8 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. TEVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 72 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.013) is normal, around the industry mean (8.801). P/E Ratio (64.468) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.980) is also within normal values, averaging (2.152). Dividend Yield (0.009) settles around the average of (0.044) among similar stocks. P/S Ratio (2.589) is also within normal values, averaging (178.797).
HROW | TEVA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 11 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 87 Overvalued | 77 Overvalued | |
PROFIT vs RISK RATING 1..100 | 63 | 8 | |
SMR RATING 1..100 | 99 | 72 | |
PRICE GROWTH RATING 1..100 | 78 | 38 | |
P/E GROWTH RATING 1..100 | 14 | 8 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TEVA's Valuation (77) in the Pharmaceuticals Generic industry is in the same range as HROW (87) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to HROW’s over the last 12 months.
TEVA's Profit vs Risk Rating (8) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (63) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than HROW’s over the last 12 months.
TEVA's SMR Rating (72) in the Pharmaceuticals Generic industry is in the same range as HROW (99) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to HROW’s over the last 12 months.
TEVA's Price Growth Rating (38) in the Pharmaceuticals Generic industry is somewhat better than the same rating for HROW (78) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew somewhat faster than HROW’s over the last 12 months.
TEVA's P/E Growth Rating (8) in the Pharmaceuticals Generic industry is in the same range as HROW (14) in the Pharmaceuticals Other industry. This means that TEVA’s stock grew similarly to HROW’s over the last 12 months.
| HROW | TEVA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 78% | N/A |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 83% | 2 days ago 73% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 65% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 72% |
| Advances ODDS (%) | 2 days ago 82% | 3 days ago 76% |
| Declines ODDS (%) | 16 days ago 79% | 7 days ago 67% |
| BollingerBands ODDS (%) | 2 days ago 75% | 2 days ago 67% |
| Aroon ODDS (%) | 2 days ago 85% | 2 days ago 77% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
HROW’s FA Score shows that 1 FA rating(s) are green while TEVA’s FA Score has 2 green FA rating(s).
- HROW’s FA Score: 1 green, 4 red.
- TEVA’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
HROW’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 4 bullish TA indicator(s).
- HROW’s TA Score: 5 bullish, 3 bearish.
- TEVA’s TA Score: 4 bullish, 3 bearish.
Price Growth
HROW (@Pharmaceuticals: Generic) experienced а +6.54% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +3.13% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.24%. For the same industry, the average monthly price growth was -9.52%, and the average quarterly price growth was +5.69%.
Reported Earning Dates
HROW is expected to report earnings on Nov 09, 2026.
TEVA is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (+0.24% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
HROW and
Correlation & Price change
A.I.dvisor indicates that over the last year, HROW has been loosely correlated with AQST. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if HROW jumps, then AQST could also see price increases.
| Ticker / NAME | Correlation To HROW | 1D Price Change % | ||
|---|---|---|---|---|
| HROW | 100% | +1.10% | ||
| AQST - HROW | 34% Loosely correlated | +3.93% | ||
| AMRX - HROW | 30% Poorly correlated | -1.40% | ||
| RMTI - HROW | 27% Poorly correlated | +6.56% | ||
| AYTU - HROW | 27% Poorly correlated | +3.68% | ||
| TEVA - HROW | 27% Poorly correlated | -1.04% | ||
More | ||||
TEVA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.
| Ticker / NAME | Correlation To TEVA | 1D Price Change % | ||
|---|---|---|---|---|
| TEVA | 100% | -1.04% | ||
| AMRX - TEVA | 39% Loosely correlated | -1.40% | ||
| VTRS - TEVA | 33% Loosely correlated | +0.27% | ||
| COLL - TEVA | 28% Poorly correlated | +1.00% | ||
| HROW - TEVA | 26% Poorly correlated | +1.10% | ||
| SNDL - TEVA | 26% Poorly correlated | -0.77% | ||
More | ||||